Clinical Trials
29 trialsNCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT05947500 2026-05-13
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03271372 2026-05-12
ADAM
University of Washington
Phase 3 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT04792073 2026-04-07
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT03944941 2026-02-05
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT06939036 2026-02-05
SANTANA-225
Ariceum Therapeutics GmbH
Phase 1/2 Terminated
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
NCT05222932 2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1 Active not recruiting
NCT03747484 2025-03-06
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT03167164 2025-02-21
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03853317 2024-08-09
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
Phase 2 Terminated
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT04393753 2024-05-08
MERKLIN2
4SC AG
Phase 2 Completed
NCT02155647 2024-03-13
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
Phase 2 Completed
NCT04551885 2023-09-21
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03787602 2023-03-02
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Kartos Therapeutics, Inc.
Phase 1/2 Unknown
NCT03905135 2022-09-13
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02584829 2022-03-22
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01772004 2021-12-20
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
Phase 1 Completed
NCT04874831 2021-11-18
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
Phase 2 Withdrawn
NCT03089658 2019-10-09
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Merck KGaA, Darmstadt, Germany
Approved for marketing